
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k122633
B. Purpose for Submission:
New device
C. Measurand:
d-Amphetamine, Secobarbital, Buprenorphine Glucuroide, Oxazepam, Benzoylecgonine,
3,4-methylenedioxymethamphetamine, Methamphetamine, Methadone, Moprhine,
Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline, 11-nor-∆9-Tetrahydrocannabinol-
9-carboxylic acid
D. Type of Test:
Qualitative lateral flow immunoassay
E. Applicant:
Branan Medical Corporation
F. Proprietary and Established Names:
ToxCup® Drug Screen Cup
G. Regulatory Information:

--- Page 2 ---
Product Classification Regulation Section Panel
Code
LDJ II 862.3870 Cannabinoid test system Toxicology (91)
Toxicology (91)
DIO II 862.3250 Cocaine and cocaine metabolite
test system
Toxicology (91)
DJG II 862.3650 Opiate test system
Toxicology (91)
DJC II 862.3610 Methamphetamine test system
Toxicology (91)
DKZ II 862.3100 Amphetamine test system
LCM unclassifed Enzyme immunoassay Phencyclidine Toxicology (91)
Toxicology (91)
JXM II 862.3170 Benzodiazepine test system
Toxicology (91)
DIS II 862.3150 Barbiturate test system
Toxicology (91)
DJR II 862.3620 Methadone test system
LFG II 862.3910 Tricyclic antidepressant drugs Toxicology (91)
test system
JXN II 862.3700 Propoxyphene test system Toxicology (91)
H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indications(s) for use:
The ToxCup Drug Screen Cup is an in vitro screening test for the rapid detection of
multiple drugs and drug metabolites in human urine at or above the following cutoff
concentration:
2

[Table 1 on page 2]
Product
Code	Classification	Regulation Section	Panel
LDJ	II	862.3870 Cannabinoid test system	Toxicology (91)
DIO	II	862.3250 Cocaine and cocaine metabolite
test system	Toxicology (91)
DJG	II	862.3650 Opiate test system	Toxicology (91)
DJC	II	862.3610 Methamphetamine test system	Toxicology (91)
DKZ	II	862.3100 Amphetamine test system	Toxicology (91)
LCM	unclassifed	Enzyme immunoassay Phencyclidine	Toxicology (91)
JXM	II	862.3170 Benzodiazepine test system	Toxicology (91)
DIS	II	862.3150 Barbiturate test system	Toxicology (91)
DJR	II	862.3620 Methadone test system	Toxicology (91)
LFG	II	862.3910 Tricyclic antidepressant drugs
test system	Toxicology (91)
JXN	II	862.3700 Propoxyphene test system	Toxicology (91)

--- Page 3 ---
Abbreviation Analyte Cutoff
AMP Amphetamine 500 ng/mL
BAR Secobarbitol 300 ng/mL
BUPG Buprenorphine Glucuronide 10 ng/mL
BZO Oxazepam 300 ng/mL
COC Benzoylecgonine 150 ng/mL
MDMA 3,4-methylenedioxymethamphetamine 500 ng/mL
MET Methamphetamine 500 ng/mL
MTD Methadone 300 ng/mL
OPI Morphine 300 ng/mL
OXY Oxycodone 100 ng/mL
PCP Phencyclidine 25 ng/mL
PPX Propoxyphene 300 ng/mL
TCA Nortriptyline 1000 ng/mL
11-nor- 9-Tetrahydrocannabinol-9-
THC 50 ng/mL
carboxylic acid
These tests provide visual qualitative results and are intended for in vitro diagnostic use
only. The ToxCup Drug Screen Cup is available in double drug analyte cassette dip
format. It is intended for prescription point-of-care use and over-the-counter consumer
use.
These tests provide only a preliminary test result and are the first step in a two-step
process for detecting drugs of abuse in urine. The second step is confirming the results in
a certified laboratory. For a quantitative result or to confirm preliminary positive results
obtained by the ToxCup Drug Screen Cup, a more specific alternative method such as
Gas Chromatography/Mass Spectrometry (GC/MS) must be used. Clinical consideration
and professional judgment must be applied to any drug of abuse test result, particularly
when a preliminary positive result is indicated.
3. Special conditions for use statement(s):
For over-the counter use.
4. Special instrument requirements:
Not Applicable
3

[Table 1 on page 3]
Abbreviation	Analyte	Cutoff
AMP	Amphetamine	500 ng/mL
BAR	Secobarbitol	300 ng/mL
BUPG	Buprenorphine Glucuronide	10 ng/mL
BZO	Oxazepam	300 ng/mL
COC	Benzoylecgonine	150 ng/mL
MDMA	3,4-methylenedioxymethamphetamine	500 ng/mL
MET	Methamphetamine	500 ng/mL
MTD	Methadone	300 ng/mL
OPI	Morphine	300 ng/mL
OXY	Oxycodone	100 ng/mL
PCP	Phencyclidine	25 ng/mL
PPX	Propoxyphene	300 ng/mL
TCA	Nortriptyline	1000 ng/mL
THC	11-nor- 9-Tetrahydrocannabinol-9-
carboxylic acid	50 ng/mL

--- Page 4 ---
I. Device Description:
This device is to be used with human urine samples. The tests are available in the cassette
dip format. The cassette format consists of the ToxCup Drug Screen Cup test strips, a plastic
cassette dip and a plastic cup base. The plastic cassette dip can hold up to 7 individual test
strips. Each test strip can detect up to 2 drugs.
Each test strip consists of an absorbent pad used to deliver sample to the test strip, a drug
antibody-colloidal gold conjugate pad, two stripes of drug protein conjugate known as Test
regions (T) and a control stripe of goat anti-rabbit IgG antibody (C).
J. Substantial Equivalence Information:
1. Predicate device name(s):
Amedica Home Drug Test Cup
2. Predicate 510(k) number(s):
k082898
3. Comparison with predicate:
4

--- Page 5 ---
Reagent Similarities and Differences
Feature Candidate Device: ToxCup Drug Predicate Device:
Screen Cup (k122633) Amedica Home Drug
Test Cup (k082898)
Intended/Indications Same
Screening Device
for Use
Methodology Competitive immunoassay Same
Results Qualitative Same
Matrix Human Urine Same
Cut Off Value THC: 50 ng/mL THC: 50 ng/mL
Amphetamine: 500 ng/mL Amphetamine: 1000
Secobarbital: 300 ng/mL ng/mL
Buprenorphine Glucuronide: 10 Secobarbital: 300 ng/mL
ng/mL Morphine: 300 ng/mL
Benzoylecgonine: 150 ng/mL Benzodiazepines 300
MDMA: 500 ng/mL ng/mL
Methamphetamine: 500ng/mL Methadone: 300 ng/mL
Methadone: 300 ng/mL Oxycodone 100 ng/mL
Morphine: 300 ng/mL MDMA: 500 ng/mL
Phencyclidine 25 ng/mL Nortriptyline 1000 ng/mL
Benzodiazepines 300 ng/mL Phencyclidine 25 ng/mL
Nortriptyline 1000 ng/mL
Oxycodone 100 ng/mL
Propoxyphene 300 ng/mL
Configurations Strip, Cassette Card
Intended Use Over the Counter and Prescription Over the Counter
Use
Test Strip Tests up to 14 drugs Tests up to 12 drugs
Method ≥ 95% ≥ 93%
Comparison Total
% agreement
Storage Sealed Pouch at15-30°C Sealed pouch at 2-30°C
Reading Time 5-8 minutes 4-5 minutes
K. Standard/ Guidance Document Referenced (if applicable):
• In Vitro Diagnostic Devices; Guidance for the Preparation of 510(k) Submission
• Premarket Submission and Labeling Recommendations for Drugs of Abuse Screening
Tests, Draft Guidance
L. Test Principle:
The tests are available in the cassette dip format. Each test strip consists of an absorbent pad
used to deliver sample to the test strip, a drug antibody-colloidal gold conjugate pad, two
5

[Table 1 on page 5]
Reagent Similarities and Differences								
	Feature			Candidate Device: ToxCup Drug			Predicate Device:	
				Screen Cup (k122633)			Amedica Home Drug	
							Test Cup (k082898)	
Intended/Indications
for Use			Screening Device			Same		
Methodology			Competitive immunoassay			Same		
Results			Qualitative			Same		
Matrix			Human Urine			Same		
Cut Off Value			THC: 50 ng/mL
Amphetamine: 500 ng/mL
Secobarbital: 300 ng/mL
Buprenorphine Glucuronide: 10
ng/mL
Benzoylecgonine: 150 ng/mL
MDMA: 500 ng/mL
Methamphetamine: 500ng/mL
Methadone: 300 ng/mL
Morphine: 300 ng/mL
Phencyclidine 25 ng/mL
Benzodiazepines 300 ng/mL
Nortriptyline 1000 ng/mL
Oxycodone 100 ng/mL
Propoxyphene 300 ng/mL			THC: 50 ng/mL
Amphetamine: 1000
ng/mL
Secobarbital: 300 ng/mL
Morphine: 300 ng/mL
Benzodiazepines 300
ng/mL
Methadone: 300 ng/mL
Oxycodone 100 ng/mL
MDMA: 500 ng/mL
Nortriptyline 1000 ng/mL
Phencyclidine 25 ng/mL		
Configurations			Strip, Cassette			Card		
Intended Use			Over the Counter and Prescription
Use			Over the Counter		
Test Strip			Tests up to 14 drugs			Tests up to 12 drugs		
Method
Comparison Total
% agreement			≥ 95%			≥ 93%		
Storage			Sealed Pouch at15-30°C			Sealed pouch at 2-30°C		
Reading Time			5-8 minutes			4-5 minutes		

--- Page 6 ---
stripes of drug protein conjugate known as Test regions (T) and a control stripe of goat anti-
rabbit IgG antibody (C).
When the absorbent end of the test device is immersed into the urine sample, the urine is
absorbed into the device by capillary action, mixes with the antibody-dye conjugate, and
flows across the pre-coated membrane. When sample drug levels are zero or below the
target cut off (the detection sensitivity of the test), antibody-dye conjugate binds to the drug-
protein conjugate immobilized in the T region of the device. This produces a colored Test
line, which regardless of its intensity, indicates a negative result.
When sample drug levels are at or above the target cutoff, the free drug in the binding
sample binds to the antibody-dye conjugate preventing the antibody-dye conjugate from
binding to the drug-protein conjugate immobilized in the T region of the device. This
prevents the development of a distinct colored band in the test region, indicating a
potentially positive result.
To serve as a procedure control, a colored line will appear at the C Region, if the test has
been performed properly because of the antibody-dye conjugate binding to anti-rabbit IgG
immobilized in the C Region of the device.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
The precision study was performed by taking negative urine samples and spiking these
with: ± 25, 50, 75, and 100% of the different cut-off values for each drug. The study
was performed at three different point-of-care sites for a minimum of 10 days. Each of
the three sites had one operator perform the studies on one lot of cups for a total of
three lots studied. All samples were randomized and masked three lots drug screen
cups were used. A summary of the results is presented in the tables below.
11-nor-9-Tetrahydrocannabinol-9-carboxylic acid = 50 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 6/9 2/13 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 7/8 1/14 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 15/0 8/7 1/14 0/15 0/15 0/15
3
6

[Table 1 on page 6]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	6/9	2/13	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	7/8	1/14	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	15/0	8/7	1/14	0/15	0/15	0/15

--- Page 7 ---
Benzoylecgonine = 150 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 6/9 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 4/11 0/15 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 15/0 4/11 0/15 0/15 0/15 0/15
3
Morphine = 300 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 13/2 6/9 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 12/3 4/11 0/15 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 14/1 4/11 0/15 0/15 0/15 0/15
3
Methamphetamine = 500 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
105/0 15/0 15/0 15/0 7/8 1/14 0/15 0/15 0/15
1
Site
105/0 15/0 15/0 15/0 8/7 1/13 0/15 0/15 0/15
2
Site
105/0 15/0 15/0 15/0 10/5 1/14 0/15 0/15 0/15
3
7

[Table 1 on page 7]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	6/9	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	4/11	0/15	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	15/0	4/11	0/15	0/15	0/15	0/15

[Table 2 on page 7]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	13/2	6/9	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	12/3	4/11	0/15	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	14/1	4/11	0/15	0/15	0/15	0/15

[Table 3 on page 7]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	105/0	15/0	15/0	15/0	7/8	1/14	0/15	0/15	0/15
Site
2	105/0	15/0	15/0	15/0	8/7	1/13	0/15	0/15	0/15
Site
3	105/0	15/0	15/0	15/0	10/5	1/14	0/15	0/15	0/15

--- Page 8 ---
Amphetamine = 500 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 13/2 6/9 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 5/10 1/14 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 15/0 4/11 2/13 0/15 0/15 0/15
3
Oxazepam = 300 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 15/0 5/10 0/15 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 3/12 0/15 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 15/0 4/11 1/14 0/15 0/15 0/15
3
Secobarbital = 300 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 6/9 2/13 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 7/8 1/14 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 15/0 8/7 1/14 0/15 0/15 0/15
3
8

[Table 1 on page 8]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	13/2	6/9	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	5/10	1/14	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	15/0	4/11	2/13	0/15	0/15	0/15

[Table 2 on page 8]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	15/0	5/10	0/15	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	3/12	0/15	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	15/0	4/11	1/14	0/15	0/15	0/15

[Table 3 on page 8]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	6/9	2/13	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	7/8	1/14	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	15/0	8/7	1/14	0/15	0/15	0/15

--- Page 9 ---
Methadone = 300 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 6/9 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 4/11 0/15 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 15/0 4/11 0/15 0/15 0/15 0/15
3
Buprenorphine Glucoronide = 10 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 13/2 6/9 0/15 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 12/3 7/8 0/15 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 14/1 9/6 0/15 0/15 0/15 0/15
3
Nortriptyline = 1000 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 8/7 2/13 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 12/3 2/13 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 14/1 13/2 2/13 0/15 0/15 0/15
3
9

[Table 1 on page 9]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	6/9	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	4/11	0/15	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	15/0	4/11	0/15	0/15	0/15	0/15

[Table 2 on page 9]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	13/2	6/9	0/15	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	12/3	7/8	0/15	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	14/1	9/6	0/15	0/15	0/15	0/15

[Table 3 on page 9]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	8/7	2/13	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	12/3	2/13	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	14/1	13/2	2/13	0/15	0/15	0/15

--- Page 10 ---
3,4-methylenedioxymethamphetamine = 500 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 4/11 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 13/2 5/10 15/0 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 15/0 7/8 15/0 0/15 0/15 0/15
3
Oxycodone = 100 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 15/0 7/8 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 8/7 0/15 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 15/0 12/3 1/14 0/15 0/15 0/15
3
Phencyclidine = 25 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 15/0 9/6 1/14 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 15/0 10/5 2/13 0/15 0/15 0/15
2
Site
120-0 15/0 15/0 15/0 10/5 2/13 0/15 0/15 0/15
3
10

[Table 1 on page 10]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	4/11	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	13/2	5/10	15/0	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	15/0	7/8	15/0	0/15	0/15	0/15

[Table 2 on page 10]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	15/0	7/8	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	8/7	0/15	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	15/0	12/3	1/14	0/15	0/15	0/15

[Table 3 on page 10]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	15/0	9/6	1/14	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	15/0	10/5	2/13	0/15	0/15	0/15
Site
3	120-0	15/0	15/0	15/0	10/5	2/13	0/15	0/15	0/15

--- Page 11 ---
Propoxyphene = 300 ng/mL cut-off
Site Negative -75% -50% -25% Cut-off +25% +50% +75% + 100%
Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off Cut-off
Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos Neg/Pos
Site
120/0 15/0 15/0 14/1 4/11 0/15 0/15 0/15 0/15
1
Site
120/0 15/0 15/0 13/2 2/13 0/15 0/15 0/15 0/15
2
Site
120/0 15/0 15/0 13/2 5/10 0/15 0/15 0/15 0/15
3
b. Linearity/assay reportable range:
Not Applicable, the assay is intended for qualitative use
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Control standards are not supplied with this device; however, this device has internal
process controls. A colored line appearing in the control region confirms sufficient
sample volume and adequate membrane wicking. Users are informed that the test is
invalid if a line fails to appear in the control region.
Professional users are informed in the labeling that external negative and positive urine
controls should be used to initially test each new lot of product to ensure proper
performance.
Stability
Accelerated stability studies were conducted on three lots of the ToxCup® Drug Screen
Tests. Protocols and acceptance criteria were found to be acceptable. The manufacturer
claims an 18 month shelf life. Real time studies are on-going.
Read time stability was performed for the ToxCup® Drug Screen Tests. A drug-free
urine sample was spiked with the appropriate drug at ± 25%, 50%, and +200% of the
cutoff. 20 replicates per level were tested at 2-10 minute intervals from 1-60 minutes.
Data supports the recommended read time of 5-8 minutes.
d. Detection limit:
Not applicable, this is a qualitative assay.
11

[Table 1 on page 11]
Site	Negative	-75%
Cut-off	-50%
Cut-off	-25%
Cut-off	Cut-off	+25%
Cut-off	+50%
Cut-off	+75%
Cut-off	+ 100%
Cut-off
	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos	Neg/Pos
Site
1	120/0	15/0	15/0	14/1	4/11	0/15	0/15	0/15	0/15
Site
2	120/0	15/0	15/0	13/2	2/13	0/15	0/15	0/15	0/15
Site
3	120/0	15/0	15/0	13/2	5/10	0/15	0/15	0/15	0/15

--- Page 12 ---
e. Analytical specificity:
Cross reactivity was established by spiking structurally related compounds into drug
free urine and diluting each to determine the lowest concentration that produced a
false positive result. Two devices were tested for each spiked urine solution. Results
are expressed as the response equivalent to cutoff, which is the lowest interference
concentration that produces a positive result. The percent cross-reactivity, expressed
as 100* (cutoff/response equivalent to cutoff) is also presented below:
Structurally related:
11-nor-9- Response % Cross Reactivity
Tetrahydrocannabinol-9- Equivalent to
carboxylic acid Cutoff (ng/mL)
(Cutoff = 50 ng/ml)
Cannabinol 50000 0.1%
Cannabidiol 100000 0.05%
11-nor-∆9-Tetrahydrocannabinol- 50 100%
9-carboxylic acid
11-nor-∆8-Tetrahydrocannabinol- 50 100%
9-carboxylic acid
11-hydroxy-∆9- 2500 2%
Tetrahydrocannabinol
∆8-Tetrahydrocannabinol 7000 0.71%
∆9-Tetrahydrocannabinol 10500 0.48%
Benzoylecgonine Response % Cross Reactivity
(Cutoff = 150 ng/ml) Equivalent to
Cutoff (ng/mL)
Benzoylecgonine 150 100%
Ecgonine 65500 0.23%
12

[Table 1 on page 12]
11-nor-9-
Tetrahydrocannabinol-9-
carboxylic acid
(Cutoff = 50 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Cannabinol	50000	0.1%
Cannabidiol	100000	0.05%
11-nor-∆9-Tetrahydrocannabinol-
9-carboxylic acid	50	100%
11-nor-∆8-Tetrahydrocannabinol-
9-carboxylic acid	50	100%
11-hydroxy-∆9-
Tetrahydrocannabinol	2500	2%
∆8-Tetrahydrocannabinol	7000	0.71%
∆9-Tetrahydrocannabinol	10500	0.48%

[Table 2 on page 12]
Benzoylecgonine
(Cutoff = 150 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Benzoylecgonine	150	100%
Ecgonine	65500	0.23%

--- Page 13 ---
Morphine Response % Cross Reactivity
(Cutoff = 300 ng/ml) Equivalent to
Cutoff (ng/mL)
6-Acetylmorphine 500 60%
6-Acetylcodeine 600 50%
Codeine 300 100%
Dihydrocodeine 500 60%
Ethyl Morphine 300 100%
Heroin 100 300%
Hydrocodone 1000 30%
Hydromorphone 400 75%
Morphine 300 100%
Morphine-3-β-glururonide 500 60%
Nalorphine 5000 6%
Methamphetamine Response % Cross Reactivity
(Cutoff = 500 ng/ml) Equivalent to
Cutoff (ng/mL)
Ephedrine 10000 5%
p-hydroxymethamphetamine 1750 28.57%
D,1-3,4-MDMA 1000 50%
d-methamphetamine 500 100%
l-methamphetamine 25000 2%
Procaine 50000 1%
d,1-3,4-MDEA 20000 2.5%
Trimethobenzamine 75000 0.67%
Amphetamine Response % Cross Reactivity
(Cutoff = 500 ng/ml) Equivalent to
Cutoff (ng/mL)
1-Amphetamine 20000 2.5%
d-Amphetamine 500 100%
D,1-3,4- 1500 33.3%
methylenedioxyamphtamine
(MDA)
Phentermine 1000 50%
β-phenylethylamine 80000 0.63%
13

[Table 1 on page 13]
Morphine
(Cutoff = 300 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
6-Acetylmorphine	500	60%
6-Acetylcodeine	600	50%
Codeine	300	100%
Dihydrocodeine	500	60%
Ethyl Morphine	300	100%
Heroin	100	300%
Hydrocodone	1000	30%
Hydromorphone	400	75%
Morphine	300	100%
Morphine-3-β-glururonide	500	60%
Nalorphine	5000	6%

[Table 2 on page 13]
Methamphetamine
(Cutoff = 500 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Ephedrine	10000	5%
p-hydroxymethamphetamine	1750	28.57%
D,1-3,4-MDMA	1000	50%
d-methamphetamine	500	100%
l-methamphetamine	25000	2%
Procaine	50000	1%
d,1-3,4-MDEA	20000	2.5%
Trimethobenzamine	75000	0.67%

[Table 3 on page 13]
Amphetamine
(Cutoff = 500 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
1-Amphetamine	20000	2.5%
d-Amphetamine	500	100%
D,1-3,4-
methylenedioxyamphtamine
(MDA)	1500	33.3%
Phentermine	1000	50%
β-phenylethylamine	80000	0.63%

--- Page 14 ---
Oxazepam Response % Cross Reactivity
Cutoff= 300 ng/ml Equivalent to
Cutoff (ng/mL)
Alprazolam 150 200%
a-hydroxyalprazolam 50 600%
Bromazepam 800 37.5
Chlordiazepoxide 3000 37.5%
Clonazepam 4000 7.5%
Clobazam 200 150%
Delorazepam 6000 5%
Diazepam 150 200%
Estazolam 300 100%
Flunitrazepam 1000 30%
Flurazepam 300 100%
Lorazepam 1500 20%
Lormetazepam 1000 30%
Medazepam 2000 15%
Nitrazepam 1000 30%
Nordiazepam 100 300%
Oxazepam 300 100%
Phenazepam 1000 30%
Prazepam 1000 30%
Temazepam 150 50%
Trazolam 1500 20%
Secobarbital Response % Cross Reactivity
Cutoff= 300 ng/ml) Equivalent to
Cutoff (ng/mL)
Amobarbital 1500 20%
Alphenal 400 75%
Aprobarbital 400 150%
Allobarbital 1500 20
Butabarbital 400 75%
Butethal 400 75%
Butalbital 300 100%
Barbital 400 75%
Secobarbital 300 100%
Pentobarbital 400 75%
Phenobarbital 400 75%
14

[Table 1 on page 14]
Oxazepam
Cutoff= 300 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Alprazolam	150	200%
a-hydroxyalprazolam	50	600%
Bromazepam	800	37.5
Chlordiazepoxide	3000	37.5%
Clonazepam	4000	7.5%
Clobazam	200	150%
Delorazepam	6000	5%
Diazepam	150	200%
Estazolam	300	100%
Flunitrazepam	1000	30%
Flurazepam	300	100%
Lorazepam	1500	20%
Lormetazepam	1000	30%
Medazepam	2000	15%
Nitrazepam	1000	30%
Nordiazepam	100	300%
Oxazepam	300	100%
Phenazepam	1000	30%
Prazepam	1000	30%
Temazepam	150	50%
Trazolam	1500	20%

[Table 2 on page 14]
Secobarbital
Cutoff= 300 ng/ml)	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Amobarbital	1500	20%
Alphenal	400	75%
Aprobarbital	400	150%
Allobarbital	1500	20
Butabarbital	400	75%
Butethal	400	75%
Butalbital	300	100%
Barbital	400	75%
Secobarbital	300	100%
Pentobarbital	400	75%
Phenobarbital	400	75%

--- Page 15 ---
Methadone Response % Cross Reactivity
Cutoff= 300 ng/ml Equivalent to
Cutoff (ng/mL)
Doxylamine 50,000 0.6%
w-Ethylidene-1,5 Dimethyl-1,3 50,000 0.6%
Diphenylapyrolidine
Methadone 300 100%
Pheniramine 75,000 0.4%
Buprenorphine Glucuronide Response % Cross Reactivity
Cutoff= 10 ng/ml Equivalent to
Cutoff (ng/mL)
Buprenorphine 100 10%
Buprenorphine Glucuronide 10 100%
Norbuprenorphine 100 10%
Norbuprenorphine Glucuronide 100 10%
Nortriptyline Response % Cross Reactivity
Cutoff= 1000 ng/ml Equivalent to
Cutoff (ng/mL)
Amitriptyline 1000 100%
Clomipramine 7500 13.33%
Cyclobenzaprine 1500 66.67%
Desipramine 750 133.33%
Doxepin 1000 100%
Imipramine 750 133.33%
Nordoxepin 1000 100%
Nortriptyline 1000 100%
Perphenazine 50000 2%
Promazine 10,000 10
Protriptyline 350 285.7%
Trimipramine 1500 66.67%
15

[Table 1 on page 15]
Methadone
Cutoff= 300 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Doxylamine	50,000	0.6%
w-Ethylidene-1,5 Dimethyl-1,3
Diphenylapyrolidine	50,000	0.6%
Methadone	300	100%
Pheniramine	75,000	0.4%

[Table 2 on page 15]
Buprenorphine Glucuronide
Cutoff= 10 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Buprenorphine	100	10%
Buprenorphine Glucuronide	10	100%
Norbuprenorphine	100	10%
Norbuprenorphine Glucuronide	100	10%

[Table 3 on page 15]
Nortriptyline
Cutoff= 1000 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Amitriptyline	1000	100%
Clomipramine	7500	13.33%
Cyclobenzaprine	1500	66.67%
Desipramine	750	133.33%
Doxepin	1000	100%
Imipramine	750	133.33%
Nordoxepin	1000	100%
Nortriptyline	1000	100%
Perphenazine	50000	2%
Promazine	10,000	10
Protriptyline	350	285.7%
Trimipramine	1500	66.67%

--- Page 16 ---
3,4 Response % Cross Reactivity
methylenediozymethamphetamine Equivalent to
Cutoff= 500 ng/ml Cutoff (ng/mL)
d,1-3,4-MDA 2000 25%
d,1-3,4-MDEA 250 200%
d,1-3,4-MDMA 500 100%
d-Methamphetamine 50,000 1%
Oxycodone Response % Cross Reactivity
Cutoff= 100 ng/ml Equivalent to
Cutoff (ng/mL)
Codeine 5000 2%
Dihydrocodeine 2000 5%
6-Acetylcodeine 15,000 0.67%
Hyrdrocodone 300 33.3%
Oxymorphone 3000 3.3%
Oxycodone 100 100%
Hydromorphone 25,000 0.4%
Ethylmorphine 5000 2%
Phencyclidine Response % Cross Reactivity
Cutoff= 25 ng/ml Equivalent to
Cutoff (ng/mL)
4-Hydroxy Phencyclidine 500 5%
Metaphit 500 5%
Phencyclidine 25 100%
Phencyclidine Morpholine 50,000 0.05%
Propoxyphene Response % Cross Reactivity
Cutoff= 300 ng/ml Equivalent to
Cutoff (ng/mL)
Propoxyphene 300 100%
Norpropoxyphene 500 60%
Structurally Un-related Compounds:
This study was performed by spiking structurally unrelated compounds and endogenous
substances up to concentration of 100 µg/mL into urine samples containing drug at ±
50% of the respective drug cutoff concentrations. Testing was performed for on two
devices for each urine control. The following compounds showed no interference
when tested at the ± 50 % drug concentration.
16

[Table 1 on page 16]
3,4
methylenediozymethamphetamine
Cutoff= 500 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
d,1-3,4-MDA	2000	25%
d,1-3,4-MDEA	250	200%
d,1-3,4-MDMA	500	100%
d-Methamphetamine	50,000	1%

[Table 2 on page 16]
Oxycodone
Cutoff= 100 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Codeine	5000	2%
Dihydrocodeine	2000	5%
6-Acetylcodeine	15,000	0.67%
Hyrdrocodone	300	33.3%
Oxymorphone	3000	3.3%
Oxycodone	100	100%
Hydromorphone	25,000	0.4%
Ethylmorphine	5000	2%

[Table 3 on page 16]
Phencyclidine
Cutoff= 25 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
4-Hydroxy Phencyclidine	500	5%
Metaphit	500	5%
Phencyclidine	25	100%
Phencyclidine Morpholine	50,000	0.05%

[Table 4 on page 16]
Propoxyphene
Cutoff= 300 ng/ml	Response
Equivalent to
Cutoff (ng/mL)	% Cross Reactivity
Propoxyphene	300	100%
Norpropoxyphene	500	60%

--- Page 17 ---
Acetaminophen Gentisic acid Riboflavin
Acetone Glutethimide Salicylic Acid
Guaiaicol Glyceryl
Albumin Ether Serotonin
Acetylsalicyclic Acid D-(+)-glucose Sodium Chloride
Amoxapine Hemoglobin Sulfamethazine
Amoxicillin Hippuric Acid Sulindac
Ampicillin Hydrochlorthiazide Tetracycline
Ascorbic Acid Hydrocortisone Thiamine
Apomorphine Ibuprofen Thioridazine
Aspartame (+/-)-Isoproterenol Trifluoperazine
Atropine Sulfate Ketamine HCl Tryptamine
Benzilic Acid Lidocaine d,l-Tryptophan
Benzoicaine Meperidine Tyramine
Benzoic Acid Methylphenamine d,l-Tyrosine
Bilirubin Methaqualone Uric Acid
2-Methylamine-
Brompheniramine Propiophenone HCl Verapamil
(1R,2S)-(+)-N-Methyl-
Benzphetamine Ephedrine Zomepirac
Cholesterol Methylphenidate Cocaine
Caffeine Nalidixic acid Setraline
Ecgonine Methyl
(+/-) Chlorpheniramine Naloxone Ester
Chlorpromazine Naproxen Amitripytiline
Chlorquine Diphosphase Niacinamide Ephedrine
Cortisone S (-)-Nicotine pheniramine
Cotinine Norepinephrine β-phenylethylamine
Creatinine Norethinodrone procaine
Creatine HCl Oxalic Acid
Deoxycorticosterone
acetate Oxolinic Acid
Dextromethorphan Papaverine
Diphenydramine Penicillin-G
Dopamine Pentazocaine
4-Dimethylaminotipyrine Phenothiazine
Ecgonine methyl ester Phenylephrine
(-) Epinephrine Prednisone
b- Estradiol Promethazine
Estrone-3-sulfate
potassium salt d-Pseudophedrine
Ethanol Pyrrolidine
Ethyl-p-aminobenzoate Quinidine
Erythromycin Quinine
Furosemide Ranitidine
17

--- Page 18 ---
The pH of a drug-free urine pool was adjusted to pH 3, pH 3.5, pH 4, pH 4.5, pH 5,
pH 5.5, pH 6, pH 6.5, pH 7, pH 7.5, pH 8, pH 8.5 or pH 9; the urine was spiked with
± 50% of the cut-off concentration for each drug and two replicates were tested for
each test. Altering the pH of the urine sample did not affect the accuracy of any of
the test results.
The specific gravity of a drug-free urine pool was measured by obtaining urine
samples with specific gravities of 1.005, 1.010, 1.020, and 1.030 and spiking with ±
50% of the cut-off concentration of the cut-off concentration for each drug and two
replicates were tested for each test. Altering the specific gravity of the urine sample
did not affect the accuracy of any of the test results.
f. Assay cut-off:
Characterization of how the device performs analytically around the claimed
cutoff concentration appears in the precision section, M1.a, above.
2. Comparison studies:
a. Method comparison with predicate device:
The method comparison study was conducted to evaluate the performance of the
device for detection of the different analytes at one point of care site using blind
labeled urine samples and one lot of ToxCup Drug Screen Cups. For each drug test,
at least 40 unaltered positive clinical samples and 40 unaltered negative clinical
samples with known GC/MS or LC/MS values were tested. At least 10% of these
samples had drug concentrations within the range of cutoff to +50% cutoff. For the
phencyclidine test, four diluted urine samples were used in the study. The results of
the studies are presented below:
18

--- Page 19 ---
Analyte Negative Low Near Near High Percent
Negative Cutoff Cutoff positive Agreement
by Negative Positive by
GC/MS by by GC/MS
(less GC/MS GC/MS (greater
than (between (between than
50%) 50% cutoff 40%
and and
cutoff) 50%)
Amphetamine Positive 0 0 2 5 36 100%
Negative 36 1 2 0 0 95.1%
Positive 0 0 3 4 39 100%
Oxazepam
Negative 36 0 1 0 0 92.5%
Positive 0 0 1 6 33 95.1%
Secobarbital
Negative 36 0 3 2 0 97.5%
Positive 0 0 0 3 36 97.5%
Methadone
Negative 36 0 4 1 0 100%
Buprenorphine Positive 0 0 1 4 38 97.7%
Glucuronide Negative 36 0 3 1 0 97.5%
Positive 0 0 0 27 11 92.7%
Nortriptyline
Negative 36 0 4 3 0 100%
3,4 methylenediozy- Positive 0 0 1 3 40 97.7%
Methamphetamine Negative 36 0 3 1 0 97.5%
Positive 0 0 2 6 38 100%
Oxycodone
Negative 36 0 4 0 0 95.2%
Positive 0 0 0 3 36 95.1%
Phencyclidine
Negative 36 0 4 2 0 100%
Positive 0 0 2 4 36 100%
Propoxyphene
Negative 36 0 2 0 0 95%
11-nor-9- Positive 0 0 1 6 35 100%
Tetrahydrocannabinol- Negative 36 2 4 0 0 97.7%
9-carboxylic acid
Positive 0 0 3 7 34 100%
Morphine
Negative 36 0 1 0 0 92.5%
Positive 0 0 0 5 67 96%
Methamphetamine
Negative 36 2 4 3 0 100%
Positive 0 0 3 3 37 97.6%
Benzoylecgonine
Negative 36 0 2 1 0 92.7%
19

[Table 1 on page 19]
Analyte		Negative	Low
Negative
by
GC/MS
(less
than
50%)	Near
Cutoff
Negative
by
GC/MS
(between
50%
and
cutoff)	Near
Cutoff
Positive
by
GC/MS
(between
cutoff
and
50%)	High
positive
by
GC/MS
(greater
than
40%	Percent
Agreement
Amphetamine	Positive	0	0	2	5	36	100%
	Negative	36	1	2	0	0	95.1%
Oxazepam	Positive	0	0	3	4	39	100%
	Negative	36	0	1	0	0	92.5%
Secobarbital	Positive	0	0	1	6	33	95.1%
	Negative	36	0	3	2	0	97.5%
Methadone	Positive	0	0	0	3	36	97.5%
	Negative	36	0	4	1	0	100%
Buprenorphine
Glucuronide	Positive	0	0	1	4	38	97.7%
	Negative	36	0	3	1	0	97.5%
Nortriptyline	Positive	0	0	0	27	11	92.7%
	Negative	36	0	4	3	0	100%
3,4 methylenediozy-
Methamphetamine	Positive	0	0	1	3	40	97.7%
	Negative	36	0	3	1	0	97.5%
Oxycodone	Positive	0	0	2	6	38	100%
	Negative	36	0	4	0	0	95.2%
Phencyclidine	Positive	0	0	0	3	36	95.1%
	Negative	36	0	4	2	0	100%
Propoxyphene	Positive	0	0	2	4	36	100%
	Negative	36	0	2	0	0	95%
11-nor-9-
Tetrahydrocannabinol-
9-carboxylic acid	Positive	0	0	1	6	35	100%
	Negative	36	2	4	0	0	97.7%
Morphine	Positive	0	0	3	7	34	100%
	Negative	36	0	1	0	0	92.5%
Methamphetamine	Positive	0	0	0	5	67	96%
	Negative	36	2	4	3	0	100%
Benzoylecgonine	Positive	0	0	3	3	37	97.6%
	Negative	36	0	2	1	0	92.7%

--- Page 20 ---
The discordant results are listed in the table below.
Cutoff value Assay Drug Metabolite GC/MS value (ng/mL)
(ng/mL) (POS/NEG)
Drug/Metabolite GC/MS value
(ng/mL)
THC 50 Positive 11-Δ9-THC-COOH 36
Cocaine 150 Positive Benzoylecgonine 120
Cocaine 150 Positive Benzoylecgonine 138
Cocaine 150 Positive Benzoylecgonine 140
Cocaine 150 Negative Benzoylecgonine 194
Opiate 300 Positive Morphine 196
Opiate 300 Positive Morphine 251
Opiate 300 Positive Morphine 291
Methamphetamine Negative d-Methamphetamine 544
500
Methamphetamine Negative d-Methamphetamine 652
500
Methamphetamine Negative d-Methamphetamine 677
500
Amphetamine 500 Positive d-Amphetamine 395
Amphetamine 500 Positive d-Amphetamine 405
Benzodiazepine 300 Positive Oxazepam 132
Benzodiazepine 300 Positive Oxazepam 224
Benzodiazepine 300 Positive Oxazepam 268.4
Barbiturate 300 Positive Butalbital 202
Barbiturate 300 Negative Butalbital 311
Barbiturate 300 Negative Butalbital 357
Methadone 300 Negative Methadone 304.8
Buprenorphine 10 Positive Buprenorphine 8.2
Glucuronide
Buprenorphine 10 Negative Buprenorphine 11
Glucuronide
Tricyclic Negative Nortriptyline 1018
Antidepressants 1000
Tricyclic Negative Nortriptyline 1065
Antidepressants 1000
Tricyclic Negative Nortriptyline 1176
Antidepressants 1000
3,4 methylenediozy- Positive 3,4 methylenediozy- 320
Methamphetamine Methamphetamine
3,4 methylenediozy- Negative 3,4 methylenediozy- 505
Methamphetamine Methamphetamine
Oxycodone 100 Positive Oxycodone 54.7
Oxycodone 100 Positive Oxycodone 79.3
20

[Table 1 on page 20]
Cutoff value
(ng/mL)	Assay
(POS/NEG)	Drug Metabolite GC/MS value (ng/mL)	
		Drug/Metabolite	GC/MS value
(ng/mL)
THC 50	Positive	11-Δ9-THC-COOH	36
Cocaine 150	Positive	Benzoylecgonine	120
Cocaine 150	Positive	Benzoylecgonine	138
Cocaine 150	Positive	Benzoylecgonine	140
Cocaine 150	Negative	Benzoylecgonine	194
Opiate 300	Positive	Morphine	196
Opiate 300	Positive	Morphine	251
Opiate 300	Positive	Morphine	291
Methamphetamine
500	Negative	d-Methamphetamine	544
Methamphetamine
500	Negative	d-Methamphetamine	652
Methamphetamine
500	Negative	d-Methamphetamine	677
Amphetamine 500	Positive	d-Amphetamine	395
Amphetamine 500	Positive	d-Amphetamine	405
Benzodiazepine 300	Positive	Oxazepam	132
Benzodiazepine 300	Positive	Oxazepam	224
Benzodiazepine 300	Positive	Oxazepam	268.4
Barbiturate 300	Positive	Butalbital	202
Barbiturate 300	Negative	Butalbital	311
Barbiturate 300	Negative	Butalbital	357
Methadone 300	Negative	Methadone	304.8
Buprenorphine 10	Positive	Buprenorphine
Glucuronide	8.2
Buprenorphine 10	Negative	Buprenorphine
Glucuronide	11
Tricyclic
Antidepressants 1000	Negative	Nortriptyline	1018
Tricyclic
Antidepressants 1000	Negative	Nortriptyline	1065
Tricyclic
Antidepressants 1000	Negative	Nortriptyline	1176
3,4 methylenediozy-
Methamphetamine	Positive	3,4 methylenediozy-
Methamphetamine	320
3,4 methylenediozy-
Methamphetamine	Negative	3,4 methylenediozy-
Methamphetamine	505
Oxycodone 100	Positive	Oxycodone	54.7
Oxycodone 100	Positive	Oxycodone	79.3

--- Page 21 ---
Phencyclidine 25 Negative Phencyclidine 29
Phencyclidine 25 Negative Phencyclidine 31
Propoxyphene 300 Positive Propoxyphene 273.1
Propoxyphene 300 Positive Propoxyphene 278
A lay-user study was performed to assess the suitability of the device for home
use. Seven drug-free urine sample pools were spiked to 0, ± 25%, ± 50%, ± 75%
of the cutoff of target drug. These concentrations were confirmed by GC/MS and
one lot of ToxCup Drug Screen Cup was tested. The testing was performed at
three sites by 153 blinded consumers divided between three sites (a minimum of
45 participants per site). Each participant received the package inset, 1-3 blinded
samples, and 1-3 ToxCup Drug Screen Cups. The lay persons test result was
compared to the GC/MS result to demonstrate accuracy by lay-users.
The participant’s ages ranged from 18-over 55 and there were slightly more males
than females. They come from a variety of career and education backgrounds. All
participants stated that the ToxCup Drug Screen Cup was easy to use, the test
results were easy to read and the instructions for confirmation of the test were
easy to understand.
Additionally, a Flesh-Kincaid reading analysis revealed that both package inserts
had a reading grade level of 7.
21

[Table 1 on page 21]
Phencyclidine 25	Negative	Phencyclidine	29
Phencyclidine 25	Negative	Phencyclidine	31
Propoxyphene 300	Positive	Propoxyphene	273.1
Propoxyphene 300	Positive	Propoxyphene	278

--- Page 22 ---
The following are the results of the lay-user study pooled together from all three sites:
11-nor-9-Tetrahydrocannabinol-9-carboxylic acid
% of Cutoff Number 11-nor-9- Lay person Percentage of
of Tetrahydrocannabinol- results: Correct
Samples 9-carboxylic acid Pos/Neg Results
GS/MS Concentration
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 12.4 0/30 100
Cutoff
-50 % 30 26.7 0/30 100
Cutoff
-25 % 30 37.4 5/25 83.0
Cutoff
+25% 30 62.9 27/3 90.0
Cutoff
+50 % 30 76.5 30/0 100
Cutoff
+75 % 30 86.4 30/0 100
Cutoff
Benzoylecgonine
% of Cutoff Number Benzoylecgonine Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 37.5 0/30 100
Cutoff
-50 % 30 79 0/30 100
Cutoff
-25 % 30 119 4/26 87.0
Cutoff
+25% 30 198 26/4 87.0
Cutoff
+50 % 30 227 30/0 100
Cutoff
+75 % 30 236 30/0 100
Cutoff
22

[Table 1 on page 22]
% of Cutoff	Number
of
Samples	11-nor-9-
Tetrahydrocannabinol-
9-carboxylic acid
GS/MS Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct
Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	12.4	0/30	100
-50 %
Cutoff	30	26.7	0/30	100
-25 %
Cutoff	30	37.4	5/25	83.0
+25%
Cutoff	30	62.9	27/3	90.0
+50 %
Cutoff	30	76.5	30/0	100
+75 %
Cutoff	30	86.4	30/0	100

[Table 2 on page 22]
% of Cutoff	Number
of
Samples	Benzoylecgonine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	37.5	0/30	100
-50 %
Cutoff	30	79	0/30	100
-25 %
Cutoff	30	119	4/26	87.0
+25%
Cutoff	30	198	26/4	87.0
+50 %
Cutoff	30	227	30/0	100
+75 %
Cutoff	30	236	30/0	100

--- Page 23 ---
Morphine
% of Cutoff Number Morphine Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 75 0/30 100
Cutoff
-50 % 30 129 0/30 100
Cutoff
-25 % 30 200 5/25 83.0
Cutoff
+25% 30 322 27/3 90.0
Cutoff
+50 % 30 484 30/0 100
Cutoff
+75 % 30 475 30/0 100
Cutoff
Methamphetamine
% of Cutoff Number Methamphetamine Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 130 0/30 100
Cutoff
-50 % 30 266 0/30 100
Cutoff
-25 % 30 413 4/26 87.0
Cutoff
+25% 30 586 26/4 87.0
Cutoff
+50 % 30 811 30/0 100
Cutoff
+75 % 30 944 30/0 100
Cutoff
23

[Table 1 on page 23]
% of Cutoff	Number
of
Samples	Morphine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	75	0/30	100
-50 %
Cutoff	30	129	0/30	100
-25 %
Cutoff	30	200	5/25	83.0
+25%
Cutoff	30	322	27/3	90.0
+50 %
Cutoff	30	484	30/0	100
+75 %
Cutoff	30	475	30/0	100

[Table 2 on page 23]
% of Cutoff	Number
of
Samples	Methamphetamine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	130	0/30	100
-50 %
Cutoff	30	266	0/30	100
-25 %
Cutoff	30	413	4/26	87.0
+25%
Cutoff	30	586	26/4	87.0
+50 %
Cutoff	30	811	30/0	100
+75 %
Cutoff	30	944	30/0	100

--- Page 24 ---
Amphetamine
% of Cutoff Number Amphetamine Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 133 0/30 100
Cutoff
-50 % 30 280 0/30 100
Cutoff
-25 % 30 389 4/26 87.0
Cutoff
+25% 30 663 26/4 87.0
Cutoff
+50 % 30 740 30/0 100
Cutoff
+75 % 30 939 30/0 100
Cutoff
Oxazepam
% of Cutoff Number Oxazepam Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 82 0/30 100
Cutoff
-50 % 30 160 0/30 100
Cutoff
-25 % 30 245 5/25 83.0
Cutoff
+25% 30 403 26/4 87.0
Cutoff
+50 % 30 465 30/0 100
Cutoff
+75 % 30 535 30/0 100
Cutoff
24

[Table 1 on page 24]
% of Cutoff	Number
of
Samples	Amphetamine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	133	0/30	100
-50 %
Cutoff	30	280	0/30	100
-25 %
Cutoff	30	389	4/26	87.0
+25%
Cutoff	30	663	26/4	87.0
+50 %
Cutoff	30	740	30/0	100
+75 %
Cutoff	30	939	30/0	100

[Table 2 on page 24]
% of Cutoff	Number
of
Samples	Oxazepam
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	82	0/30	100
-50 %
Cutoff	30	160	0/30	100
-25 %
Cutoff	30	245	5/25	83.0
+25%
Cutoff	30	403	26/4	87.0
+50 %
Cutoff	30	465	30/0	100
+75 %
Cutoff	30	535	30/0	100

--- Page 25 ---
Secobarbital
% of Cutoff Number Secobarbital Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 77 0/30 100
Cutoff
-50 % 30 133 0/30 100
Cutoff
-25 % 30 235 4/26 87.0
Cutoff
+25% 30 333 26/4 87.0
Cutoff
+50 % 30 448 30/0 100
Cutoff
+75 % 30 489 30/0 100
Cutoff
Methadone
% of Cutoff Number Methadone Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 78.7 0/30 100
Cutoff
-50 % 30 165 0/30 100
Cutoff
-25 % 30 217 4/26 87.0
Cutoff
+25% 30 366 25/5 83.0
Cutoff
+50 % 30 480 30/0 100
Cutoff
+75 % 30 547 30/0 100
Cutoff
25

[Table 1 on page 25]
% of Cutoff	Number
of
Samples	Secobarbital
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	77	0/30	100
-50 %
Cutoff	30	133	0/30	100
-25 %
Cutoff	30	235	4/26	87.0
+25%
Cutoff	30	333	26/4	87.0
+50 %
Cutoff	30	448	30/0	100
+75 %
Cutoff	30	489	30/0	100

[Table 2 on page 25]
% of Cutoff	Number
of
Samples	Methadone
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	78.7	0/30	100
-50 %
Cutoff	30	165	0/30	100
-25 %
Cutoff	30	217	4/26	87.0
+25%
Cutoff	30	366	25/5	83.0
+50 %
Cutoff	30	480	30/0	100
+75 %
Cutoff	30	547	30/0	100

--- Page 26 ---
Buprenorphine Glucuronide
% of Cutoff Number Buprenorphine Lay person Percentage of
of Glucuronide results: Correct Results
Samples GS/MS Pos/Neg
Concentration
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 2.5 0/30 100
Cutoff
-50 % 30 4.5 0/30 100
Cutoff
-25 % 30 8 5/25 83.0
Cutoff
+25% 30 12.3 29/1 97.0
Cutoff
+50 % 30 14 30/0 100
Cutoff
+75 % 30 15.3 30/0 100
Cutoff
Nortriptyline
% of Cutoff Number Nortriptyline Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 222 0/30 100
Cutoff
-50 % 30 436 0/30 100
Cutoff
-25 % 30 723 4/26 87.0
Cutoff
+25% 30 1105 26/4 87.0
Cutoff
+50 % 30 1508 30/0 100
Cutoff
+75 % 30 1761 30/0 100
Cutoff
26

[Table 1 on page 26]
% of Cutoff	Number
of
Samples	Buprenorphine
Glucuronide
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	2.5	0/30	100
-50 %
Cutoff	30	4.5	0/30	100
-25 %
Cutoff	30	8	5/25	83.0
+25%
Cutoff	30	12.3	29/1	97.0
+50 %
Cutoff	30	14	30/0	100
+75 %
Cutoff	30	15.3	30/0	100

[Table 2 on page 26]
% of Cutoff	Number
of
Samples	Nortriptyline
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	222	0/30	100
-50 %
Cutoff	30	436	0/30	100
-25 %
Cutoff	30	723	4/26	87.0
+25%
Cutoff	30	1105	26/4	87.0
+50 %
Cutoff	30	1508	30/0	100
+75 %
Cutoff	30	1761	30/0	100

--- Page 27 ---
3,4 methylenediozy-Methamphetamine
% of Cutoff Number 3,4 Lay person Percentage of
of methylenediozy- results: Correct Results
Samples Methamphetamine Pos/Neg
GS/MS
Concentration
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 130 0/30 100
Cutoff
-50 % 30 256 0/30 100
Cutoff
-25 % 30 382 4/26 87.0
Cutoff
+25% 30 626 28/2 93.0
Cutoff
+50 % 30 838 30/0 100
Cutoff
+75 % 30 917 30/0 100
Cutoff
Oxycodone
% of Cutoff Number Oxycodone Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 27.8 0/30 100
Cutoff
-50 % 30 51 0/30 100
Cutoff
-25 % 30 82 4/26 80.0
Cutoff
+25% 30 124 27/3 90.0
Cutoff
+50 % 30 145 30/0 100
Cutoff
+75 % 30 178 30/0 100
Cutoff
27

[Table 1 on page 27]
% of Cutoff	Number
of
Samples	3,4
methylenediozy-
Methamphetamine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	130	0/30	100
-50 %
Cutoff	30	256	0/30	100
-25 %
Cutoff	30	382	4/26	87.0
+25%
Cutoff	30	626	28/2	93.0
+50 %
Cutoff	30	838	30/0	100
+75 %
Cutoff	30	917	30/0	100

[Table 2 on page 27]
% of Cutoff	Number
of
Samples	Oxycodone
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	27.8	0/30	100
-50 %
Cutoff	30	51	0/30	100
-25 %
Cutoff	30	82	4/26	80.0
+25%
Cutoff	30	124	27/3	90.0
+50 %
Cutoff	30	145	30/0	100
+75 %
Cutoff	30	178	30/0	100

--- Page 28 ---
Phencyclidine
% of Cutoff Number Phencyclidine Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
Negative 210 0 0/210 100
-75 % 30 6.9 0/30 100
Cutoff
-50 % 30 13.7 0/30 100
Cutoff
-25 % 30 17.2 4/26 87.0
Cutoff
+25% 30 29.2 25/5 83.0
Cutoff
+50 % 30 38.7 30/0 100
Cutoff
+75 % 30 46.3 30/0 100
Cutoff
Propoxyphene
% of Cutoff Number Propoxyphene Lay person Percentage of
of GS/MS results: Correct Results
Samples Concentration Pos/Neg
(ng/mL)
-100% of 210 0 0/210 100
the Cut-off
-75 % 30 74 0/30 100
Cutoff
-50 % 30 153 0/30 100
Cutoff
-25 % 30 204 4/26 87.0
Cutoff
+25% 30 337 28/2 93.0
Cutoff
+50 % 30 424 30/0 100
Cutoff
+75 % 30 506 30/0 100
Cutoff
28

[Table 1 on page 28]
% of Cutoff	Number
of
Samples	Phencyclidine
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
Negative	210	0	0/210	100
-75 %
Cutoff	30	6.9	0/30	100
-50 %
Cutoff	30	13.7	0/30	100
-25 %
Cutoff	30	17.2	4/26	87.0
+25%
Cutoff	30	29.2	25/5	83.0
+50 %
Cutoff	30	38.7	30/0	100
+75 %
Cutoff	30	46.3	30/0	100

[Table 2 on page 28]
% of Cutoff	Number
of
Samples	Propoxyphene
GS/MS
Concentration
(ng/mL)	Lay person
results:
Pos/Neg	Percentage of
Correct Results
-100% of
the Cut-off	210	0	0/210	100
-75 %
Cutoff	30	74	0/30	100
-50 %
Cutoff	30	153	0/30	100
-25 %
Cutoff	30	204	4/26	87.0
+25%
Cutoff	30	337	28/2	93.0
+50 %
Cutoff	30	424	30/0	100
+75 %
Cutoff	30	506	30/0	100

--- Page 29 ---
The overall percent agreement between the Lay person and the GC/MS method was:
Overall
Analyte Percent
Agreement
11-nor- 9-Tetrahydrocannabinol-9-
96.1%
carboxylic acid
Benzoylecgonine 96.3%
Morphine 96.1%
Methamphetamine 96.3%
Amphetamine 95.2%
Oxazepam 95.7%
Secobarbitol 96.3%
Methadone 95.7%
Buprenorphine Glucuronide 97.1%
96.3%
Nortriptyline
3,4-methylenedioxymethamphetamine 97.1%
Oxycodone 95.7%
Phencyclidine 94.7%
Propoxyphene 96.1%
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not Applicable
b. Clinical specificity:
Not Applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not Applicable
29

[Table 1 on page 29]
Analyte	Overall
Percent
Agreement
11-nor- 9-Tetrahydrocannabinol-9-
carboxylic acid	96.1%
Benzoylecgonine	96.3%
Morphine	96.1%
Methamphetamine	96.3%
Amphetamine	95.2%
Oxazepam	95.7%
Secobarbitol	96.3%
Methadone	95.7%
Buprenorphine Glucuronide	97.1%
Nortriptyline	96.3%
3,4-methylenedioxymethamphetamine	97.1%
Oxycodone	95.7%
Phencyclidine	94.7%
Propoxyphene	96.1%

--- Page 30 ---
4. Clinical cut-off:
Not Applicable
5. Expected values/Reference range
Specific ranges for each analyte/methodology are listed in the package insert.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
30